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Abstract 
Purpose: The CIGMA study investigated a novel human polyclonal antibody preparation (trimodulin) contain‑
ing ~ 23% immunoglobulin (Ig) M, ~ 21% IgA, and ~ 56% IgG as add‑on therapy for patients with severe community‑
acquired pneumonia (sCAP).
Methods: In this double‑blind, phase II study (NCT01420744), 160 patients with sCAP requiring invasive mechani‑
cal ventilation were randomized (1:1) to trimodulin (42 mg IgM/kg/day) or placebo for five consecutive days. Primary 
endpoint was ventilator‑free days (VFDs). Secondary endpoints included 28‑day all‑cause and pneumonia‑related 
mortality. Safety and tolerability were monitored. Exploratory post hoc analyses were performed in subsets stratified 
by baseline C‑reactive protein (CRP; ≥ 70 mg/L) and/or IgM (≤ 0.8 g/L).
Results: Overall, there was no statistically significant difference in VFDs between trimodulin (mean 11.0, median 11 
[n = 81]) and placebo (mean 9.6; median 8 [n = 79]; p = 0.173). Twenty‑eight‑day all‑cause mortality was 22.2% vs. 
27.8%, respectively (p = 0.465). Time to discharge from intensive care unit and mean duration of hospitalization were 
comparable between groups. Adverse‑event incidences were comparable. Post hoc subset analyses, which included 
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Introduction
Community-acquired pneumonia (CAP) has an inci-
dence of ~ 1.2 per 1000 persons per year in Europe, vary-
ing with region, age, and comorbidities [1]. Up to 21% of 
hospitalized patients with CAP are admitted to inten-
sive care units (ICUs), thus impacting healthcare costs 
and clinical outcomes [2]. Severe CAP (sCAP), usually 
defined as CAP that requires treatment in an ICU, is 
associated with high mortality of up to 58% [3].
Antibiotic therapy with supportive care alone has lim-
ited success in sCAP; hence, targeting inflammatory 
responses may improve patient outcomes. This approach 
is supported by the observation that a systemic and com-
plex cytokine response (interleukin-6 and -10) is linked 
to greater mortality in patients with CAP, irrespective of 
the presence of sepsis [4]. Further, therapeutic response 
and treatment outcomes in acute respiratory distress syn-
drome may be worse in patients with a hyperinflamma-
tory disease phenotype [5]. A recombinant tissue factor 
pathway inhibitor, activated protein C, corticosteroids, 
intravenous immunoglobulins (Igs), and intravenous 
IgM-enriched Igs have been investigated for their poten-
tial as add-on therapies targeted at the immune response 
in patients with sCAP [6–9].
IgM plays a critical role in the immediate defense 
against severe bacterial infection. Reduced IgM levels 
have been observed in patients with CAP, sepsis, and 
severe pandemic influenza; consequently, interest in add-
on therapy with IgM-enriched preparations has increased 
[10–12]. The evidence for IgM-enriched Ig prepara-
tions in patients with severe sepsis and septic shock is 
incompletely understood, although systematic reviews 
have generally concluded that IgM-enriched Ig prepara-
tions are associated with a reduction in mortality [6, 7]. 
Relevant mechanisms of action include opsonization of 
causal pathogens, neutralization of microbial pathogens 
and virulence factors, and modulation of the inflamma-
tory response [13–15].
Trimodulin is a novel human plasma-derived native 
polyclonal antibody preparation for intravenous admin-
istration [16, 17]. Trimodulin contains IgM (~ 23%), IgA 
(~ 21%), and IgG (~ 56%).
The CIGMA (Concentrated IgM for Application) study 
reported here aimed to evaluate the efficacy and safety of 
trimodulin as an add-on therapy in patients with sCAP 
requiring invasive mechanical ventilation (IMV).
Methods
Study design and patient population
The CIGMA study (NCT01420744 [18, 19]), a rand-
omized, placebo-controlled, double-blind, multicenter, 
parallel-group, phase II trial, was conducted in hospi-
tals in Germany, Spain, and the UK. The study was con-
ducted in accordance with the International Council for 
Harmonisation, Good Clinical Practice standards, and 
the Declaration of Helsinki, and with local institutional 
review board/independent ethics committee approval. 
All patients (or their representatives) provided written 
informed consent.
Patients ≥ 18 years of age with sCAP (diagnosed clini-
cally and radiologically), requiring IMV and receiving 
standard antibiotics, were enrolled. Patients with sus-
pected hospital-acquired pneumonia; severe lung dis-
eases interfering with sCAP therapy (e.g., cystic fibrosis); 
life expectancy of ≤ 28  days due to medical conditions 
not related to sCAP or to sCAP-associated sepsis; selec-
tive, absolute IgA deficiency with antibodies to IgA, neu-
trophil count < 1000/mm3; or platelet count < 50,000/
mm3 were excluded. Study-specific guidance on IMV, 
weaning procedures based on the concept of lung-pro-
tective ventilation, and on antibiotic treatment according 
to the Infectious Diseases Society of America/American 
the majority of patients (58–78%), showed significant reductions in all‑cause mortality (trimodulin vs. placebo) in 
patients with high CRP, low IgM, and high CRP/low IgM at baseline.
Conclusions: No significant differences were found in VFDs and mortality between trimodulin and placebo groups. 
Post hoc analyses supported improved outcome regarding mortality with trimodulin in subsets of patients with 
elevated CRP, reduced IgM, or both. These findings warrant further investigation.
Trial registration: NCT01420744.
Keywords: Trimodulin, Polyclonal antibody, Severe community‑acquired pneumonia, Add‑on therapy, 
Immunoglobulin M
Take‑home message 
In mechanically ventilated patients with severe community‑
acquired pneumonia, add‑on therapy with trimodulin, a novel 
polyclonal antibody preparation, did not statistically significantly 
increase ventilator‑free days (primary endpoint) vs. placebo. 
 Exploratory post hoc analyses suggest reductions in mortality for 
trimodulin compared with placebo in subsets of patients with 
elevated C‑reactive protein levels and/or reduced immunoglobu‑
lin M levels, and warrant investigation in a phase III study with a 
targeted patient population.
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Thoracic Society consensus guidelines on the manage-
ment of CAP in adults was provided to minimize poten-
tial differences among sites and countries [18, 20].
Eligible patients were randomized 1:1 to receive either 
trimodulin (5% protein solution; BT086; Biotest AG, 
Dreieich, Germany) or an equal volume of human albu-
min as placebo (1% protein solution), both as intravenous 
infusion. Dosing of trimodulin based on IgM content 
(42  mg  IgM/kg body weight) or placebo was once daily 
for five consecutive days. Infusion was initiated ≥ 1 and 
≤ 12  h following commencement of IMV at a rate of 
0.1 mL/min, increasing by 0.1 mL every 10 min to a max-
imum of 0.5 mL/min (target infusion rate).
Patients were followed until day  28 or hospital dis-
charge, whichever occurred first (with an additional 
safety follow-up visit at day 43 in the UK). Mortality was 
followed up until day 28 in discharged patients.
Patients were assigned a unique randomization num-
ber generated by Accovion GmbH (Eschborn, Germany; 
now Clinipace Worldwide, Morrisville, North Carolina, 
USA) using  Rando® and recorded by the investigator. 
Randomization numbers were grouped in blocks of four 
to facilitate equal distribution into the two groups. Blind-
ing was maintained by a similar appearance of placebo 
to trimodulin, and vials were covered with transparent 
colored foil.
Pathogen detection was performed according to local 
standards, with sputum and blood cultures being the 
most frequently analyzed, followed by smear and bron-
choalveolar lavage.
Efficacy assessments
The primary endpoint was ventilator-free days (VFDs), 
defined as the number of days between extubation 
from IMV to day  28 after enrollment. VFDs were set 
to “0” if the patient died before day 28 or required IMV 
for ≥ 28 days [21].
Secondary endpoints included 28-day all-cause mortal-
ity, 28-day investigator-determined pneumonia-related 
mortality, time from admission to discharge from the 
ICU, time from hospital admission to discharge, change 
in Sequential Organ Failure Assessment (SOFA) score 
(measured on days 1 and 28), and days free from ino-
trope/vasopressor (dobutamine, epinephrine, dopamine, 
or norepinephrine).
Safety
Safety was assessed throughout the trial, with events 
classified using the Medical Dictionary for Regulatory 
Activities (MedDRA) version 17.1. Treatment-emergent 
adverse events (TEAEs; defined as an adverse event [AE] 
that occurred from the time of first dose of study medica-
tion until the final follow-up visit, independent of relation 
to study drug), infusion-related reactions (defined as 
TEAEs that occurred during or within 24 h after infusion 
of study medication), vital signs, electrocardiograms, 
and laboratory parameters including clinical chemistry, 
hematology, and coagulation were recorded. Renal func-
tion was monitored through serum creatinine. Estimated 
glomerular filtration rate was calculated post hoc using 
the Chronic Kidney Disease Epidemiology Collaboration 
equation considering serum creatinine, age, gender, and 
race [22]. An independent data and safety monitoring 
board (DSMB) closely monitored the first six sequentially 
enrolled patients. The DSMB also reviewed unblinded 
safety data of patients during the course of the study.
Statistical analysis
All statistical methods, unless otherwise specified, were 
prespecified in the study protocol.
A group-sequential adaptive design was chosen that 
allowed modifications, such as sample size re-estimation 
or planning of further analyses based on interim results. 
After the first of two interim analyses, the sample size 
was adjusted to 160 patients [18].
VFDs were evaluated using a one-sided Wilcoxon–
Mann–Whitney test with an α level of 0.025. Twenty-
eight-day all-cause mortality was evaluated using the 
Kaplan–Meier method and analyzed using a Mantel–
Haenszel test. The study was powered to detect a differ-
ence of two VFDs between the treatment arms.
Efficacy analyses were performed in the intent-to-treat 
set, which included all randomized patients who received 
at least one dose of study drug and at least one efficacy 
assessment, assigned as randomized. Safety analyses 
were performed using the safety set, which comprised 
all patients who received at least one dose of study 
drug according to medication received, regardless of 
randomization.
Exploratory post hoc analyses were performed to 
identify patient subsets that may benefit most from tri-
modulin treatment. Subsets with a high mortality delta 
(defined as the difference between the percentage of 
patients who received trimodulin and died, and the per-
centage of patients who received placebo and died) were 
considered for further analyses (if the subsets were of suf-
ficient size). Markers were selected taking into account 
the possible targeting of the inflammatory response or 
immunomodulatory capacity of trimodulin [23]. C-reac-
tive protein (CRP) and IgM cutoff values were chosen 
to identify maximal differences between the trimodu-
lin and placebo groups (Supplementary Figs.  S1 and 
S2). Four subsets were identified for use in the post hoc 
analyses: patients with baseline levels of ≥ 70 mg/L CRP 
(high CRP), ≤ 0.8  g/L IgM (low IgM), CRP ≥ 70  mg/L 
and ≤ 0.8  g/L IgM (combined high CRP/low IgM), 
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and ≥ 2 ng/mL procalcitonin (high procalcitonin [PCT]). 
For statistical methods and sample size calculation, refer 
to the Supplementary Methods.
Results
A total of 161 eligible patients were enrolled (from 24/41 
sites [Germany, 10; Spain, 10; and UK, 4]) between Octo-
ber 4, 2011 and February 25, 2015; 160 patients were ran-
domized (81 trimodulin; 79 placebo) and received at least 
one dose of study medication in addition to antibiotic 
treatment. Patient disposition is shown in Fig. 1.
No significant differences in patient demographics 
and other baseline characteristics (Table 1) were identi-
fied between the treatment groups except for higher PCT 
levels and higher Acute Physiology and Chronic Health 
Evaluation (APACHE) II values in the placebo group. 
These higher levels of PCT at baseline were partially due 
to outliers (median 8.7, interquartile range [IQR] 1.9–
30.6  ng/mL). Common comorbidities included hyper-
tension, cardiac disorders, renal/urinary disorders, and 
nervous system disorders in both groups.
About 50% of patients had positive diagnosis by means 
of microbiological testing (Supplementary Table  S1). 
The most frequent pathogens identified in both groups 
were species of Streptococci and Staphylococci, and 
approximately 20% of patients were diagnosed with viral 
pneumonia.
Antibiotic treatment and use of systemic corticoster-
oids were comparable between the treatment groups 
(Supplementary Tables  S2 and S3). The majority of 
patients were treated according to the recommenda-
tions of the Infectious Diseases Society of America/
American Thoracic Society consensus guidelines on 
the management of CAP in adults and received antibi-
otic combination therapy (β-lactams + macrolides or 
β-lactams + fluoroquinolones). No significant differences 
in time to ICU admission were identified between treat-
ment groups or study centers (data not shown).
Overall, the difference in the mean number of VFDs 
(primary endpoint) between the trimodulin and placebo 
groups was 1.4 days in favor of trimodulin, which was not 
statistically significant (Table 2).
There was an absolute reduction in 28-day all-cause 
mortality of 5.6% (Table 2 and Fig. 2) and a relative reduc-
tion in mortality of 20.1% in the trimodulin group versus 
placebo. For pneumonia-related mortality, the absolute 
reduction was 6.5% (Table  2) and the relative reduction 
was 51.2%. Time to discharge from ICU to the ward, 
mean duration of hospitalization, and vasopressor-free 
days were not significantly different (Table 2).
TEAE incidences (including serious AEs [SAEs]), over-
all and throughout the majority of System Organ Classes 
(SOCs), were comparable between the trimodulin and 
placebo groups. Differences considered relevant for the 
trimodulin group were observed in the SOCs “renal and 
urinary disorders” and “hepatobiliary disorders”; these 
mainly resulted from “acute renal failure” (reported in 17 
[21%] individuals in the trimodulin group and 8 [10.1%] 
in the placebo group) and “cholestasis” (reported by 
8 [9.9%] and 2 [2.5%] individuals in the trimodulin and 
161 screened and enrolled
160 randomized
81 assigned to trimodulin 79 assigned to placebo
One patient not randomized 
due to withdrawal of informed 
consent
11 discontinued study
2 adverse event
8 moved to another hospital
1 other reason
3 discontinued study
1 adverse event
2 moved to another hospital
70 study ongoing 76 study ongoing
81 included in all 
patient analysis
79 included in all 
patient analysis
Fig. 1 Patient disposition and reasons for discontinuation during the study period
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placebo groups, respectively). There were significantly 
more TEAEs in the SOC “infections and infestations” 
reported in the placebo group (p = 0.004; Table 3).
Exploratory post hoc analyses were performed to 
identify patient subsets that may benefit most from tri-
modulin treatment (Supplementary Figs.  S1 and S2). 
Cutoff values were set to values with maximum mortal-
ity difference between the treatment groups. Only groups 
representing the majority of the study population are 
reported here. The post hoc subsets presented included 
124 (77.5%) patients with baseline levels of high CRP, 
111 (69.4%) patients with low IgM, 92 (57.5%) patients 
with combined high CRP and low IgM, and 94 (58.8%) 
patients with high PCT.
In general, no significant differences in patient demo-
graphics and other baseline characteristics were identi-
fied between the patient subsets of the treatment groups 
(Supplementary Tables  S4–7) with the following excep-
tions: lower SOFA scores and PCT values in the tri-
modulin group (CRP and PCT subsets), lower APACHE 
II scores and PCT levels in the trimodulin group (IgM 
subset), and lower levels of PCT in the trimodulin group 
(CRP/IgM subset). Adjustment for the difference in PCT 
values was performed by exclusion of PCT outliers. The 
Table 1 Demographics and other baseline characteristics in all patients
Data not available for a8 patients; b2 patients; c5 patients; d11 patients; eBaseline data substituted by day 1 data in 5 patients because of missing values. Data not 
available for 4 patients; fBaseline data substituted by day 1 data in 10 patients because of missing values. Data not available for 15 patients; gSystem Organ Class; 
hPreferred Term
Data are n (%), mean (SD), or median (IQR, 25th–75th percentile)
APACHE II Acute Physiology and Chronic Health Evaluation; BMI body mass index; CRP C-reactive protein; CURB-65 Confusion, elevated blood Urea nitrogen, 
Respiratory rate, Blood pressure, 65 years of age and older; IgM, IgG, IgA immunoglobulin M, G, and A; IQR interquartile range; PaO2/FiO2 ratio of arterial oxygen partial 
pressure to fractional inspired oxygen; PCT procalcitonin; SD standard deviation; SOFA Sequential Organ Failure Assessment score
*p values were calculated post hoc by Chi-square test for sex, two-sided t test for age, BMI,  PaO2/FiO2, IgM/A/G, CRP, and PCT; by two-sided Wilcoxon rank sum test for 
APACHE II, SOFA, and CURB-65; or by Fisher exact test for all medical history outcomes and concomitant medication
Characteristic Trimodulin (n = 81) Placebo (n = 79) p value*
Sex, n (%) 0.675
  Male 56 (69.1) 57 (72.2)
  Female 25 (30.9) 22 (27.8)
Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Age (years) 63.7 (14.5) 66 (53–75) 65.5 (14.8) 67 (57–77) 0.435
BMI (kg/m2)a 26.5 (5.0) 25.7 (23.3–29.6) 25.9 (4.7) 25.5 (23.1–28.0) 0.410
APACHE  IIb 23.1 (8.1) 23 (18–29) 26.2 (8.3) 25 (20–33) 0.036
SOFA 9.7 (3.8) 11 (7–12) 10.8 (3.5) 11 (8–14) 0.071
CURB‑65c 2.7 (1.1) 3 (2–4) 2.8 (1.3) 3 (2–4) 0.637
PaO2/FiO2
d 134.7 (72.5) 110.0 (82.0–173.6) 133.7 (72.5) 106.5 (77.0–185.7) 0.937
IgM (g/L) 0.8 (0.79) 0.6 (0.4–0.9) 0.7 (0.41) 0.6 (0.4–0.9) 0.186
IgG (g/L) 6.8 (2.73) 6.7 (5.0–8.9) 6.6 (3.04) 6.4 (4.2–8.2) 0.530
IgA (g/L) 2.3 (1.14) 2.1 (1.4–3.1) 2.5 (1.78) 2.0 (1.3–3.2) 0.322
CRP (mg/L)e 220 (130.8) 217 (121.5–325.3) 227 (147.5) 235 (88.2–333.5) 0.723
PCT (ng/mL)f 8.3 (12.9) 2.3 (0.7–10.4) 23.3 (31.75) 8.7 (1.9–30.6) 0.0004
Medical history, n (%)
  Cardiac  disordersg 39 (48.1) 41 (51.9) 0.752
  Hypertensionh 42 (51.9) 42 (53.2) 0.876
  Diabetes  mellitush 15 (18.5) 6 (7.6) 0.060
  Nervous system  disordersg 21 (25.9) 22 (27.8) 0.859
  Neoplasm (benign, malignant, and 
unspecified)g
22 (27.2) 17 (21.5) 0.463
  Renal and urinary  disordersg 41 (50.6) 40 (50.6) 1.000
  Sepsish 13 (16.0) 10 (12.7) 0.654
  Septic  shockh 35 (43.2) 44 (55.7) 0.154
  Hepatic  cirrhosish 5 (6.2) 0 (0.0) 0.059
Medication at baseline, n (%)
  Corticosteroids for systemic use 24 (29.6) 21 (26.6) 0.375
  Antivirals for systemic use 11 (13.6) 12 (15.2) 0.824
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remaining patients had comparable PCT values and still 
showed substantial mortality difference between the 
treatment arms. In summary, the difference in PCT val-
ues does not explain the observed mortality difference in 
the subsets.
The differences in mean VFDs for trimodulin ver-
sus placebo were 2.9, 3.5, 3.9, and 3.4  days in the high 
CRP, low IgM, combined high CRP/low IgM, and high 
PCT subsets, respectively (Table 4). Importantly, 28-day 
all-cause mortality was substantially reduced in the tri-
modulin group versus placebo in each subset (absolute 
reductions of 16.7%, 16.6%, 24.8%, and 8.1%, respec-
tively), with a reduction in absolute mortality of up to 
24.8% (p = 0.006) in the combined high CRP/low IgM 
subset (68.0% relative reduction; Fig.  3). Kaplan–Meier 
analyses for the high CRP, low IgM, and combined sub-
sets are presented in Supplementary Figs.  S3–5. Data 
on 28-day all-cause mortality for all patient groups ana-
lyzed, including those that did not represent the majority 
of the study population, are reported in Supplementary 
Table S8.
Discussion
The CIGMA study was designed to evaluate the efficacy 
and safety of a novel therapeutic polyclonal antibody 
preparation, trimodulin, in severely ill patients with 
sCAP.
Although the difference observed in the primary end-
point of VFDs, with a mean increase of 1.4 days and 
median increase of 3 days in favor of trimodulin, was not 
significant, this difference may be considered clinically 
relevant. According to the clinical study protocol, the 
study was powered to detect a mean difference of 2 days 
between treatment groups. Further, although the study 
was not powered for mortality, and the reductions in 
28-day all-cause and pneumonia-related mortality were 
Table 2 Overview of primary and secondary efficacy endpoints in trimodulin and placebo treatment groups in all 
patients
a Mortality is not considered for duration of mechanical ventilation; b34 patients were missing in the trimodulin group and 38 in the placebo group
ICU intensive care unit, IQR interquartile range, SD standard deviation, SOFA Sequential Organ Failure Assessment, VFD ventilator-free day
Data are n (%), mean (SD) and median (IQR, 25th–75th percentile)
*One-sided Wilcoxon–Mann–Whitney test; †Wilcoxon test; ‡Mantel–Haenszel test
Endpoint Trimodulin Placebo p value
Mean (SD) Median (IQR) Mean (SD) Median (IQR)
VFDs n  = 81 n  = 79
11.0 (9.5) 11.0 (0–20) 9.6 (9.4) 8.0 (0–19) 0.173 *
Duration of mechanical ventilation (days)a n  = 81 n  = 79
12.8 (8.5) 10.0 (6–19) 13.8 (8.6) 11.0 (7–21) Not calculated
VFDs in surviving patients n  = 63 n  = 57
14.2 (8.4) 18.0 (8–21) 13.3 (8.5) 16.0 (4–20) 0.271†
Vasopressor‑free days n  = 81 n  = 79
13.0 (8.9) 14.0 (6–20) 13.7 (8.4) 15.0 (8–20) 0.639†
Discharge time from ICU (days) n  = 81b n  = 79b
13.4 (5.9) 11.0 (9–17) 14.4 (5.8) 13.0 (10–18) 0.161†
Discharge time from hospital (days) n  = 81 n  = 79
19.5 (5.5) 20.0 (15–24) 19.0 (4.9) 19.0 (15–23) 0.479
28‑day all‑cause mortality, n (%) 18/81 (22.2) 22/79 (27.8) 0.465‡
28‑day pneumonia‑related mortality, n (%) 5/81 (6.2) 10/79 (12.7) Not calculated
Change in SOFA score from day 1 to 7 −4.8 (7.5) −7.0 (−10–0) −5.4 (6.5) −7.0 (−10 to 3.0) Not calculated
Fig. 2 Survival by treatment regimen
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not significant with add-on trimodulin compared with 
placebo, the relative reductions of 20% in all-cause mor-
tality and 51% in pneumonia-related mortality in trimod-
ulin-treated patients warrant further investigation.
In the CIGMA study, IgM levels were low in the major-
ity of patients compared with the normal range. IgM lev-
els range from 0.4 to 2.5 g/L [24]. Historical data suggest 
that low IgA and IgG levels are associated with a greater 
risk of mortality in CAP [25], and that low IgM concen-
trations in patients with sepsis or viral infections are 
related to a negative outcome [11, 12, 26].
Moreover, high CRP and PCT levels may be prognostic 
of poor outcomes in CAP [27, 28]. In our subgroup anal-
ysis, the cutoffs for levels of CRP (≥ 70  mg/L) and PCT 
(> 2  ng/mL) are comparable to historically published val-
ues, and high levels of each may generally be considered to 
indicate systemic and severe infections [29, 30]. Torres et al. 
showed that methylprednisolone reduced treatment fail-
ure compared with placebo in 120 patients with sCAP and 
a high systemic inflammatory response (CRP > 150 mg/L); 
in-hospital mortality, however, was similar [9].
In the post hoc analyses of the CIGMA study reported 
here, absolute mortality reduction was 16.7% for the 
high CRP subset, 16.6% for the low IgM subset, and 
24.8% for the combined high CRP/low IgM subset; the 
relative reduction in mortality was 54–68% in favor of 
trimodulin.
The definition of pneumonia-related death or comor-
bidity was challenging in this complex patient popula-
tion and required a subjective assessment of each case 
by the investigator. Further, comorbidities at study entry 
may particularly influence outcome in elderly patients—
the relatively high all-cause mortality in trimodulin-
treated patients > 65 years of age compared with patients 
40–65  years of age may be associated with comorbidi-
ties rather than with an underlying infection (data not 
shown). Indeed, many patients who died did not have 
elevated CRP (data not shown). Generally, diagnosis 
of CAP is complex and may result in misdiagnosis, and 
inflammation parameters, such as CRP, have been inves-
tigated to support diagnosis [31]. In a future clinical trial 
with trimodulin in sCAP, CRP could help to support the 
Table 3 Overview of treatment‑emergent adverse events (TEAEs; safety analysis set)
Data are n (%)
There were no adverse drug reactions leading to death in either treatment group
a Safety set includes patients with TEAE onset before day 28, but who died due to TEAE after day 28
b All events were reported for single patients only, except for critical illness polyneuropathy and vocal cord paralysis, each reported for 2 (2.5%) patients in the 
trimodulin group, and headache, which was reported for 3 (3.7%) patients in the trimodulin group
*p values were calculated post hoc by Fisher exact test
Trimodulin (n = 81) Placebo (n = 79) p value*
Overall incidence 75 (92.6) 75 (94.9) 0.746
TEAEs with onset during infusion and up to 24 h after infusion end 67 (82.7) 67 (84.8) 0.831
Serious TEAEs 62 (76.5) 62 (78.5) 0.850
TEAEs with fatal  outcomea 20 (24.7) 23 (29.1) 0.594
Discontinuation due to TEAEs 2 (2.5) 1 (1.3) 1.000
TEAEs by System Organ Class (≥ 5% of patients)
  Blood and lymphatic system disorders 33 (40.7) 34 (43.0) 0.873
  Cardiac disorders 31 (38.3) 27 (34.2) 0.624
  Vascular disorders 30 (37.0) 30 (38.0) 1.000
  Metabolism and nutrition disorders 29 (35.8) 29 (36.7) 1.000
  Respiratory, thoracic, and mediastinal disorders 29 (35.8) 40 (50.6) 0.079
  Gastrointestinal disorders 27 (33.3) 36 (45.6) 0.145
  Infections and infestations 27 (33.3) 45 (57.0) 0.004
  General disorders and administration‑site conditions 22 (27.2) 31 (39.2) 0.131
  Renal and urinary disorders 20 (24.7) 12 (15.2) 0.167
  Psychiatric disorders 18 (22.2) 23 (29.1) 0.367
  Investigations 15 (18.5) 13 (16.5) 0.836
  Skin and subcutaneous tissue disorders 14 (17.3) 14 (17.7) 1.000
  Nervous system  disordersb 13 (16.0) 8 (10.1) 0.350
  Hepatobiliary disorders 12 (14.8) 4 (5.1) 0.063
  Musculoskeletal and connective tissue disorders 9 (11.1) 11 (13.9) 0.639
  Injury, poisoning, and connective tissue disorders 8 (9.9) 8 (10.1) 1.000
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diagnosis and differentiate sCAP from other conditions 
(by excluding patients with similar symptoms who have 
other underlying diseases), thereby enrolling a more tar-
geted study population.
In the present study, incidences of TEAEs (including 
SAEs) were comparable between both treatment groups. 
Most patients had multiple comorbidities. SOCs with 
TEAEs reported more frequently in the trimodulin group 
Table 4 VFDs in trimodulin and placebo groups in patient subsets
Data are mean ± 95% confidence interval (CI)
CRP, IgM, and PCT were measured at baseline
CI confidence interval, CRP C-reactive protein, IgM immunoglobulin M, PCT procalcitonin, VFD ventilator-free day
*One-sided p values based on Wilcoxon rank sum test with continuity correction (0.5); significance level 0.025
Patient subset Trimodulin Placebo p value*
VFD mean (95% CI) VFD mean (95% CI)
CRP ≥ 70 mg/L n = 65 n = 59
12.1 (9.8–14.4) 9.2 (6.8–11.6) 0.044
IgM ≤ 0.8 g/L n = 56 n = 55
12.4 (10.0–14.9) 8.9 (6.5–11.4) 0.031
CRP ≥ 70 mg/L and IgM ≤ 0.8 g/L n = 51 n = 41
12.6 (10.1–15.2) 8.7 (5.8–11.6) 0.031
PCT ≥ 2 ng/mL n = 43 n = 51
11.2 (8.2–14.1) 7.8 (5.2–10.3) 0.047
Fig. 3 Twenty‑eight‑day all‑cause mortality in trimodulin and placebo treatment groups in all patients and in patient subsets. Mortality was 
assessed in all patients and in stratified patient populations based on baseline levels of C‑reactive protein (CRP) ≥ 70 mg/L, immunoglobulin (Ig) 
M ≤ 0.8 g/L, or both criteria combined, or procalcitonin (PCT) ≥ 2.0 ng/mL. Actual numbers of deaths are given at the bottom of each column
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were “renal and urinary disorders” and “hepatobiliary 
disorders” mainly resulting from patients experiencing 
“acute renal failure” (21% patients in the trimodulin group 
vs. 10.1% in the placebo group) and non-serious “choles-
tasis” (9.9% vs. 2.5%, respectively). Acute renal failure is a 
common comorbidity in sCAP [3], and is an established 
potential risk during conventional intravenous IgG treat-
ment [32]. All cases of acute renal failure in the current 
study occurred in patients with pre-existing renal impair-
ment and in patients at high risk for renal failure. Nota-
bly, the incidence of renal TEAEs in the trimodulin group 
(21%) was lower than would be expected in patients with 
sCAP, in whom the incidence of acute kidney injury has 
been reported to be up to 38% (10/26) [33].
Confounding factors were identified in all patients with 
cholestasis, including parallel intake/infusion of multi-
ple drugs with possible effects on the liver, and/or con-
founding medical history. All adverse drug reactions of 
cholestasis were reported from one study center, so the 
possibility of a treatment interaction with concomitant 
medication should be considered.
Targeting the immune response with novel therapies such 
as trimodulin may provide additional protection against 
secondary infections and reduce mortality due to infection-
related TEAEs such as sepsis. In this study, the incidence of 
TEAEs of all types of infection was significantly lower with 
trimodulin add-on treatment than with placebo, suggesting 
an additional protective effect against infection.
All of the above TEAEs are considered to be controlla-
ble under ICU conditions and close monitoring. Despite 
the failed primary endpoint, but given the trend in reduc-
tion of mortality further solidified by post hoc analyses, 
the risk profile of trimodulin is considered favorable for 
further clinical investigations.
Limitations of this study were that biomarkers and cut-
off values used in the post hoc analyses were not prespeci-
fied in the study protocol. In addition, for the stratification 
of the patients into subsets, only baseline PCT values were 
used: data from serial measurements were not considered. 
There was a significant difference in baseline PCT values, 
with higher mean values in the placebo group. Further 
statistical tests were performed to adjust for this differ-
ence (data not shown). However, the difference in baseline 
PCT values does not explain the observed mortality dif-
ferences between the treatment arms in the patient sub-
sets. In future clinical trials with trimodulin, serial PCT 
measurements will be considered, as lack of reduction 
in PCT levels may better predict treatment failure and 
mortality than absolute values. Additionally, differences 
in severity of illness (APACHE II and SOFA score) were 
observed in this study in favor of the control group. How-
ever, these differences were not significant in the high 
CRP/low IgM subset, which showed the highest survival 
benefit for trimodulin. Finally, although patients received 
antibiotics on the day of randomization, the exact time 
point of treatment initiation was not recorded.
Conclusions
The phase II CIGMA study reported here did not meet 
the primary endpoint of VFDs following add-on treat-
ment with trimodulin in severely ill patients with sCAP. 
However, post hoc analyses of patient subsets with high 
CRP, low IgM, and combined high CRP/low IgM baseline 
levels could be used to inform further investigation of tri-
modulin in a large, global phase III study that is powered 
for mortality in a targeted patient population with sCAP.
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